Known targets — ChEMBL curated mechanism
CSF1RFLT1FLT4KDRKITPDGFRAPDGFRB
The experimentally established mechanism targets of Vatalanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 19/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 18/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 8/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 7/20 | 1.00 |
| ▸ | CSF1R known ✓ | P07333 | 2/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.83 |
| ▸ | CIT | O14578 | 1/20 | 0.83 |
| ▸ | EGFR | P00533 | 1/20 | 0.83 |
| ▸ | HLA-A | P04439 | 1/20 | 0.83 |
| ▸ | RET | P07949 | 1/20 | 0.83 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.83 |
| ▸ | FRK | P42685 | 1/20 | 0.83 |
| ▸ | CDK8 | P49336 | 1/20 | 0.83 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.83 |
| ▸ | STK3 | Q13188 | 1/20 | 0.83 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.83 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.83 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.83 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vatalanib SCHEMBL675786 | 1.00 | KDR (1.00) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL1685425 | 1.00 | KDR (1.00) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL5154569 | 0.94 | KDR (0.89) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6605579 | 0.93 | KDR (0.88) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL18286 | 0.91 | FLT1 (1.00) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL29350047 | 0.91 | FLT1 (1.00) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6131019 | 0.90 | FLT1 (0.97) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL905598 | 0.90 | FLT1 (0.97) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6131017 | 0.90 | FLT1 (0.97) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL905616 | 0.90 | FLT1 (0.97) | KDRFLT1PDGFRBKITCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195478-A1 | DUAL INHIBITORS OF VISTA AND PD-1 PATHWAYS | AURIGENE ONCOLOGY LIMITED (IN) | 2025-06-19 | — | — | US | disclosed |
| US-20250144082-A1 | DUAL INHIBITORS OF TIM-3 AND PD-1 PATHWAYS | AURIGENE ONCOLOGY LIMITED (IN) | 2025-05-08 | — | — | US | disclosed |
| US-12226402-B2 | Dual inhibitors of TIM-3 and PD-1 pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2025-02-18 | — | — | US | disclosed |
| US-12064418-B2 | Conjoint therapies for immunomodulation | CURIS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-12005045-B2 | Method of modulating TIGIT and PD-1 signalling pathways using 1,2,4-oxadiazole compounds | AURIGENE ONCOLOGY LIMITED (IN) | 2024-06-11 | — | — | US | disclosed |
| US-20240122904-A1 | METHOD OF MODULATING TIGIT AND PD-1 SIGNALLING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-04-18 | — | — | US | disclosed |
| US-20240100024-A1 | DUAL INHIBITORS OF TIM-3 AND PD-1 PATHWAYS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-03-28 | — | — | US | disclosed |
| US-20230081191-A1 | CONJOINT THERAPIES FOR IMMUNOMODULATION | AURIGENE ONCOLOGY LIMITED (IN) | 2023-03-16 | — | — | US | disclosed |
| US-20230062570-A1 | DUAL INHIBITORS OF TIM-3 AND PD-1 PATHWAYS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-03-02 | — | — | US | disclosed |
| US-11497735-B2 | Conjoint therapies for immunomodulation | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-11-15 | — | — | US | disclosed |
| CN-104744215-B | Pharmaceutical composition comprising monoterpene | 尼昂克技术公司 | 2019-03-15 | — | — | CN | disclosed |
| WO-2018073754-A1 | DUAL INHIBITORS OF VISTA AND PD-1 PATHWAYS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-04-26 | — | — | WO | disclosed |
| US-20170340733-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2017-11-30 | — | — | US | disclosed |
| CN-105078973-A | Pharmaceutical compositions comprising POH derivatives | NEONC TECHNOLOGIES INC | 2015-11-25 | — | — | CN | disclosed |
| CN-103168018-B | Pharmaceutical composition comprising POH derivative | Neonc Technologies, Inc. (US) | 2015-10-21 | — | — | CN | disclosed |
| CN-104744215-A | Pharmaceutical Compositions Comprising Monoterpenes | NEONC TECHNOLOGIES INC | 2015-07-01 | — | — | CN | disclosed |
| CN-104523661-A | Therapeutic compositions comprising monoterpenes | UNIV SOUTHERN CALIFORNIA | 2015-04-22 | — | — | CN | disclosed |
| CN-102892289-B | Pharmaceutical composition comprising monoterpenes | NEONC TECHNOLOGIES INC | 2015-03-25 | — | — | CN | disclosed |
| CN-103608028-A | Human myeloid derived suppressor cell cancer markers | UNIV SOUTHERN CALIFORNIA | 2014-02-26 | — | — | CN | disclosed |
| CN-102405044-A | Therapeutic compositions containing monoterpenes | UNIV SOUTHERN CALIFORNIA | 2012-04-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100024-A1 | DUAL INHIBITORS OF TIM-3 AND PD-1 PATHWAYS | PDCD1, PDCD1LG2, CD274 | KDR 2122/4885FLT1 2019/4885PDGFRB 1417/4885 |
| US-20240122904-A1 | METHOD OF MODULATING TIGIT AND PD-1 SIGNALLING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS | PDCD1, CD274, PDCD1LG2 | KDR 991/4885FLT1 584/4885PDGFRB 922/4885 |
| US-20250144082-A1 | DUAL INHIBITORS OF TIM-3 AND PD-1 PATHWAYS | PDCD1, PDCD1LG2, CD274 | KDR 2122/4885FLT1 2019/4885PDGFRB 1417/4885 |
| US-20250195478-A1 | DUAL INHIBITORS OF VISTA AND PD-1 PATHWAYS | PDCD1, PDCD1LG2, CD274 | KDR 356/4885FLT1 743/4885PDGFRB 1615/4885 |
| US-20230081191-A1 | CONJOINT THERAPIES FOR IMMUNOMODULATION | CD274, PDCD1LG2, PDCD1 | KDR 1057/4885FLT1 794/4885PDGFRB 894/4885 |
| US-20170340733-A1 | COMBINATION THERAPIES | BRCA1, TP53, VHL | KDR 1196/4885FLT1 1395/4885PDGFRB 236/4885 |
| US-12005045-B2 | Method of modulating TIGIT and PD-1 signalling pathways using 1,2,4-oxadiazole compounds | PDCD1, CD274, PDCD1LG2 | KDR 991/4885FLT1 584/4885PDGFRB 922/4885 |
| US-12226402-B2 | Dual inhibitors of TIM-3 and PD-1 pathways | PDCD1, PDCD1LG2, CD274 | KDR 2122/4885FLT1 2019/4885PDGFRB 1417/4885 |
| US-20230062570-A1 | DUAL INHIBITORS OF TIM-3 AND PD-1 PATHWAYS | PDCD1, PDCD1LG2, CD274 | KDR 2122/4885FLT1 2019/4885PDGFRB 1417/4885 |
| US-12064418-B2 | Conjoint therapies for immunomodulation | CD274, PDCD1LG2, PDCD1 | KDR 1057/4885FLT1 794/4885PDGFRB 894/4885 |
| US-11497735-B2 | Conjoint therapies for immunomodulation | CD274, PDCD1LG2, PDCD1 | KDR 1057/4885FLT1 794/4885PDGFRB 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.